Telix Pharmaceuticals under investigation for alleged securities fraud.

Pomerantz LLP is investigating Telix Pharmaceuticals for potential securities fraud and unlawful business practices. The investigation follows the company's disclosure of a subpoena from the US Securities and Exchange Commission regarding disclosures about its prostate cancer therapeutic candidates. As a result, Telix's American Depositary Receipt price fell 10.44% to $14.58 per ADR. Investors who purchased Telix securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New York, July 2, 2025 /PRNewswire/ -- Pomerantz LLP has initiated an investigation into potential securities fraud and unlawful business practices at Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). The investigation follows the company's recent disclosure of a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures about the development of prostate cancer therapeutic candidates.

On July 22, 2025, Telix revealed that it had received a subpoena from the SEC seeking various documents and information primarily relating to the company's disclosures regarding the development of its prostate cancer therapeutic candidates. This disclosure triggered a significant drop in Telix's American Depositary Receipt (ADR) price. On July 23, 2025, the ADR price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR [1].

Investors who purchased Telix securities are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss their potential claims. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, and Paris, is recognized as a premier firm in corporate, securities, and antitrust class litigation [1].

Telix's revelation has also prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about the development and commercial prospects of its drug candidates. The firm urges Telix investors who suffered substantial losses to submit their losses now [2].

The investigation by Hagens Berman is focused on the propriety of Telix's statements concerning certain of its prostate cancer therapeutic candidates. The triggering event for this investigation was the disclosure of the SEC subpoena on July 22, 2025, which drove the price of Telix American Depositary Shares sharply lower during intraday trading on July 23, 2025 [2].

Investors are encouraged to stay informed about developments in this ongoing investigation and to seek legal advice if they believe they have been affected. For more information, investors can visit the Pomerantz LLP and Hagens Berman websites or contact their respective legal teams.

References:
[1] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited-tlx-ce7c5fdddc8bff25
[2] https://www.marketscreener.com/news/telix-pharmaceuticals-limited-tlx-shares-fall-amid-sec-subpoena-hagens-berman-ce7c5fdddd8ff025